Patents by Inventor Angela Anne Guzzetta

Angela Anne Guzzetta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predicting response to epigenetic drug therapy
    Patent number: 10619210
    Abstract: The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: April 14, 2020
    Assignee: The Johns Hopkins University
    Inventors: Nita Ahuja, Stephen B. Baylin, Katherine Chiappinelli, Angela Anne Guzzetta, Huili Li, Cynthia Zahnow
  • PREDICTING RESPONSE TO EPIGENETIC DRUG THERAPY
    Publication number: 20170009303
    Abstract: The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.
    Type: Application
    Filed: February 9, 2015
    Publication date: January 12, 2017
    Inventors: Nita Ahuja, Stephen B. Baylin, Katherine Chiappinelli, Angela Anne Guzzetta, Huili Li, Cynthia Zahnow